Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Ionis Pharmaceuticals Looks to Partners to Pay the Bills
Ionis Pharmaceuticals(NASDAQ: IONS)continues to rack up royalties from its spinal muscular atrophy drug Spinraza while the rest of its extensive pipeline basically pays the rest of the biotech's bills.
This page uses Cookies. For proper functioning of the page Cookies are needed. You agree to using Cookies by clicking "OK".
More infos can be found in our Privacy declaration.
If you disagree this service is only available in very limited ways.
